Half of the mice with a CTSD deletion in mammary epithelial cells reached an end-stage tumor burden at 28 weeks in contrast to LysM-cre;Ctsd−/− (20 weeks) and control (22 weeks) mice. This evidence concerns the gene CTSD and neoplasm.